MiNK Therapeutics Inc(INKT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 4:00 PM ET (Korea 10/30 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.4 | Insider Own | 60.1% | Shs Outstand | 5.1M | Perf Week | 6.26% |
| Market Cap | 0.05B | Forward P/E | - | EPS next Y | 0.68% | Insider Trans | -0.27% | Shs Float | 2.0M | Perf Month | -14.82% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | -0.5 | Inst Own | 4% | Short Float | 2.34% | Perf Quarter | 1.81% |
| Income | -0.01B | P/S | - | EPS this Y | 24.74% | Inst Trans | 8.64% | Short Ratio | 3.39 | Perf Half Y | -12.38% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 7.42% | ROA | -187.78% | Short Interest | 0.05M | Perf YTD | -4.13% |
| Book/sh | -2.75 | P/C | 6.19 | EPS past 3/5Y | 29.4% 9.83% | ROE | - | 52W High | -36.85% ($16.93) | Perf Year | -23.7% |
| Cash/sh | 1.73 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 26.06% ($8.48) | Perf 3Y | 17.41% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 15.65% | Gross Margin | - | Volatility(W/M) | 8.11% 6.24% | Perf 5Y | -94.02% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.71 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.23 | EPS Q/Q | 41.49% | Profit Margin | - | RSI (14) | 47.99 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.23 | Sales Q/Q | - | SMA20 | 0.23% ($10.67) | Beta | 0.47 | Target Price | $42.05 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -5.98% ($11.37) | Rel Volume | 0.69 | Prev Close | $10.8 |
| Employees | 15 | LT Debt/Eq | - | EPS/Sales Surpr. | -3.33% - | SMA200 | -5.37% ($11.3) | Avg Volume(3M) | 0.01M | Price | $10.69 |
| IPO | 2021/10/15 | Option/Short | No/Yes | Trades | 352 | Volume | 9,772 | Change | -1.02% |
A biotech company developing immune cell therapies to treat cancer. It leverages iNKT cells from the human body to create off-the-shelf cell therapies. Its lead pipeline candidate, agenT-797, is currently in a Phase 2 clinical trial for solid tumors such as gastric and esophageal cancer, and the company is headquartered in New York.
Over the past 1 year, roughly in the middle
37% below its 1-year high.
Traded less than usual. That is 69% of its average volume.
INKT has weak earning power
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +24.7% this year.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -94.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 4.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #407 of 594 in the industry
Based on market cap of $55M.
INKT#407 MiNK Therapeutics Inc $55M PER - 
ONCY#408 Oncolytics Biotech Inc $55M PER - 
HYPD#409 Hyperion DeFi Inc $54M PER - 
ALPS#410 ALPS Group Inc $54M PER - 
ELOX#411 Eloxx Pharmaceuticals Inc $54M PER - 
FAQ
What kind of company is INKT?
INKT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INKT?
The market cap of INKT is approximately $55M, ranking 4,813 within its sector.
What is the 52-week high and low for INKT?
INKT has recorded a 52-week high of $16.93 and a low of $8.48.
